Floyd Katherine, Arora V K, Murthy K J R, Lonnroth Knut, Singla Neeta, Akbar Y, Zignol Matteo, Uplekar Mukund
HIV/AIDS, TB and Malaria, World Health Organization, 1211 Geneva 27, Switzerland.
Bull World Health Organ. 2006 Jun;84(6):437-45. doi: 10.2471/blt.05.024109. Epub 2006 Jun 21.
To assess the cost and cost-effectiveness of the Public-Private Mix DOTS (PPM-DOTS) strategy for tuberculosis (TB) control in India.
We collected data on the costs and effects of pilot PPM-DOTS projects in Delhi and Hyderabad using documentary data and interviews. The cost of PPM-DOTS was compared with public sector DOTS (i.e. DOTS delivered through public sector facilities only) and non-DOTS treatment in the private sector. Costs for 2002 in US$ were assessed for the public sector, private practitioners, and patients/attendants. Effectiveness was measured as the number of cases successfully treated.
The average cost per patient treated was US$ 111-123 for PPM-DOTS and public sector DOTS, and US$ 111-172 for non-DOTS treatment in the private sector. From the public sector's perspective, the cost per patient treated was lower in PPM-DOTS projects than in public sector DOTS programmes (US$ 24-33 versus US$ 63). DOTS implementation in either the public or private sectors improved treatment outcomes and substantially lowered costs incurred by patients and their attendants, compared to non-DOTS treatment in the private sector (US$ 50-60 for DOTS compared to over US$ 100 for non-DOTS). The average cost-effectiveness of PPM-DOTS and public sector DOTS was similar, at US$ 120-140 per patient successfully treated, compared to US$ 218-338 for non-DOTS private sector treatment. Incremental cost-effectiveness analysis showed that PPM-DOTS can improve effectiveness while also lowering costs.
PPM-DOTS can be an affordable and cost-effective approach to improving TB control in India, and can substantially lower the economic burden of TB for patients.
评估公私混合直接督导下的短程化疗(PPM-DOTS)策略在印度控制结核病(TB)的成本及成本效益。
我们通过文献数据和访谈收集了德里和海得拉巴PPM-DOTS试点项目的成本及效果数据。将PPM-DOTS的成本与公共部门直接督导下的短程化疗(即仅通过公共部门设施提供的直接督导下的短程化疗)以及私营部门的非直接督导下的短程化疗进行比较。评估了2002年公共部门、私人执业医生以及患者/陪护人员以美元计算的成本。效果以成功治疗的病例数来衡量。
PPM-DOTS和公共部门直接督导下的短程化疗每位患者的平均治疗成本为111 - 123美元,私营部门非直接督导下的短程化疗为111 - 172美元。从公共部门的角度来看,PPM-DOTS项目中每位患者的治疗成本低于公共部门直接督导下的短程化疗项目(24 - 33美元对63美元)。与私营部门的非直接督导下的短程化疗相比,公共或私营部门实施直接督导下的短程化疗均改善了治疗效果,并大幅降低了患者及其陪护人员的费用(直接督导下的短程化疗为50 - 60美元,而非直接督导下的短程化疗超过100美元)。PPM-DOTS和公共部门直接督导下的短程化疗的平均成本效益相似,成功治疗每位患者的成本为120 - 140美元,相比之下,私营部门非直接督导下的短程化疗为218 - 338美元。增量成本效益分析表明,PPM-DOTS在提高效果的同时还能降低成本。
PPM-DOTS可能是印度改善结核病控制的一种经济且具成本效益的方法,并且能大幅降低患者的结核病经济负担。